FibroGen EBITDA 2013-2024 | FGEN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FibroGen ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FibroGen ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.2B
Takeda Pharmaceutical (TAK)	$43.3B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.2B
Astellas Pharma (ALPMY)	$18.2B
United Therapeutics (UTHR)	$16.1B
Summit Therapeutics (SMMT)	$14.7B
Neurocrine Biosciences (NBIX)	$12.1B
Shionogi (SGIOY)	$11.9B
Catalent (CTLT)	$10.7B
Jazz Pharmaceuticals (JAZZ)	$7.1B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.7B
Ionis Pharmaceuticals (IONS)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$5.1B
PTC Therapeutics (PTCT)	$3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2.2B
Centessa Pharmaceuticals (CNTA)	$1.9B
Evotec AG (EVO)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.8B
Xencor (XNCR)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Indivior (INDV)	$1.4B
Harrow (HROW)	$1.4B